NASDAQ:CARM

Carisma Therapeutics Stock News

Healthcare > Biotechnology

Buy CARM

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Jun 03, 2026

Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company's Lead Product Candidate Vicineum™

07:00am, Monday, 15'th Mar 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported ope

Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company's Lead Product Candidate Vicineum™

08:00am, Tuesday, 02'nd Mar 2021

Sesen Bio: Vicineum's Priority Review Provides Conviction To Hold Through PDUFA Date

01:48pm, Monday, 22'nd Feb 2021

The FDA has provided Vicineum a priority review and an August 2021 PDUFA date. Following the headline, Sesen Bio's share price spiked to a new 52-week high. Now with an accelerated timeline and no AdC

Sesen Bio: Problems Of Main Competitor Make Vicinium More Attractive

08:57am, Sunday, 21'st Feb 2021

Sesen Bio's vicinium is targeting a form of NMIBC. Its chief competitor is adstiladril, and its current position with the FDA is a bit vague.

Why Hepion Pharma, Sesen Bio And More Are Moving Today

11:44am, Tuesday, 16'th Feb 2021

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading lower Tuesday after the company priced its 44.2 million share common stock offering at $2 per share. Hepion Pharmaceuticals Inc is engaged in t

Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike

09:13am, Tuesday, 16'th Feb 2021

Under priority review status, the FDA has accepted Sesen Bio Inc's (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non